Unknown

Dataset Information

0

The emerging profile of cross-resistance among the nonnucleoside HIV-1 reverse transcriptase inhibitors.


ABSTRACT: Nonnucleoside reverse transcriptase inhibitors (NNRTIs) are widely used to treat HIV-1-infected individuals; indeed most first-line antiretroviral therapies typically include one NNRTI in combination with two nucleoside analogs. In 2008, the next-generation NNRTI etravirine was approved for the treatment of HIV-infected antiretroviral therapy-experienced individuals, including those with prior NNRTI exposure. NNRTIs are also increasingly being included in strategies to prevent HIV-1 infection. For example: (1) nevirapine is used to prevent mother-to-child transmission; (2) the ASPIRE (MTN 020) study will test whether a vaginal ring containing dapivirine can prevent HIV-1 infection in women; (3) a microbicide gel formulation containing the urea-PETT derivative MIV-150 is in a phase I study to evaluate safety, pharmacokinetics, pharmacodynamics and acceptability; and (4) a long acting rilpivirine formulation is under-development for pre-exposure prophylaxis. Given their widespread use, particularly in resource-limited settings, as well as their low genetic barriers to resistance, there are concerns about overlapping resistance between the different NNRTIs. Consequently, a better understanding of the resistance and cross-resistance profiles among the NNRTI class is important for predicting response to treatment, and surveillance of transmitted drug-resistance.

SUBMITTER: Sluis-Cremer N 

PROVIDER: S-EPMC4147682 | biostudies-literature | 2014 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

The emerging profile of cross-resistance among the nonnucleoside HIV-1 reverse transcriptase inhibitors.

Sluis-Cremer Nicolas N  

Viruses 20140731 8


Nonnucleoside reverse transcriptase inhibitors (NNRTIs) are widely used to treat HIV-1-infected individuals; indeed most first-line antiretroviral therapies typically include one NNRTI in combination with two nucleoside analogs. In 2008, the next-generation NNRTI etravirine was approved for the treatment of HIV-infected antiretroviral therapy-experienced individuals, including those with prior NNRTI exposure. NNRTIs are also increasingly being included in strategies to prevent HIV-1 infection. F  ...[more]

Similar Datasets

| S-EPMC2809083 | biostudies-literature
| S-EPMC1635531 | biostudies-literature
| S-EPMC6658764 | biostudies-literature
| S-EPMC3488198 | biostudies-literature
| S-EPMC7125863 | biostudies-literature
| S-EPMC6158299 | biostudies-literature
| S-EPMC3067143 | biostudies-literature
| S-EPMC6631718 | biostudies-literature
| S-EPMC1298242 | biostudies-literature
| S-EPMC3067126 | biostudies-literature